Brain–Gut Axis: Clinical Implications

Gastroenterology Clinics of North America

Volumn 47, Issue 4, 2018, Pages 727-739

  Khlevner, Julie ^a   Park, Yeji ^a   Margolis, Kara Gross ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Brain gut axis; Brain gut microbiome axis; Enteric nervous system; Irritable bowel syndrome; Serotonin

Indexed keywords

ALOSETRON; AMITRIPTYLINE; PROBIOTIC AGENT; SEROTONIN; SEROTONIN AGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

BRAIN; BRAIN FUNCTION; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTESTINE; INTESTINE FLORA; INTESTINE FUNCTION; IRRITABLE COLON; NEUROMODULATION; REVIEW; GASTROINTESTINAL TRACT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

BRAIN; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 85054005234     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2018.07.002     Document Type: Review

References (98)

1. Borre, Y.E., O'Keeffe, G.W., Clarke, G., et al. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med 20 (2014), 509–518.
2. Carabotti, M., Scirocco, A., Maselli, M.A., et al. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 28 (2015), 203–209.
3. Furness, J.B., Callaghan, B.P., Rivera, L.R., et al. The enteric nervous system and gastrointestinal innervation: integrated local and central control. Adv Exp Med Biol 817 (2014), 39–71.
4. Costa, M., Brookes, S.J., Hennig, G.W., Anatomy and physiology of the enteric nervous system. Gut 47:Suppl 4 (2000), iv15–iv19 [discussion: iv26].
5. Gershon, M.D., Developmental determinants of the independence and complexity of the enteric nervous system. Trends Neurosci 33 (2010), 446–456.
6. Brummelte, S., Mc Glanaghy, E., Bonnin, A., et al. Developmental changes in serotonin signaling: implications for early brain function, behavior and adaptation. Neuroscience 342 (2017), 212–231.
7. Chang, L., The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 140 (2011), 761–765.
8. Obata, Y., Pachnis, V., The effect of microbiota and the immune system on the development and organization of the enteric nervous system. Gastroenterology 151:5 (2016), 836–844.
9. Sampson, T.R., Mazmanian, S.K., Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 17 (2015), 565–576.
10. Zhao, Y., Yu, Y.B., Intestinal microbiota and chronic constipation. Springerplus, 5, 2016, 1130.
11. Quigley, E.M., Spiller, R.C., Constipation and the microbiome: lumen versus mucosa!. Gastroenterology 150 (2016), 300–303.
12. Reigstad, C.S., Salmonson, C.E., Rainey, J.F. 3rd, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J 29 (2015), 1395–1403.
13. Yarandi, S.S., Peterson, D.A., Treisman, G.J., et al. Modulatory effects of gut microbiota on the central nervous system: how gut could play a role in neuropsychiatric health and diseases. J Neurogastroenterol Motil 22 (2016), 201–212.
14. Gareau, M.G., Microbiota-gut-brain axis and cognitive function. Adv Exp Med Biol 817 (2014), 357–371.
15. Forsythe, P., Bienenstock, J., Kunze, W.A., Vagal pathways for microbiome-brain-gut axis communication. Adv Exp Med Biol 817 (2014), 115–133.
16. Mayer, E.A., Knight, R., Mazmanian, S.K., et al. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci 34 (2014), 15490–15496.
17. Yano, J.M., Yu, K., Donaldson, G.P., et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161 (2015), 264–276.
18. Smith, P.A., The tantalizing links between gut microbes and the brain. Nature 526 (2015), 312–314.
19. Francino, M.P., Early development of the gut microbiota and immune health. Pathogens 3 (2014), 769–790.
20. Thum, C., Cookson, A.L., Otter, D.E., et al. Can nutritional modulation of maternal intestinal microbiota influence the development of the infant gastrointestinal tract?. J Nutr 142 (2012), 1921–1928.
21. Al-Asmakh, M., Anuar, F., Zadjali, F., et al. Gut microbial communities modulating brain development and function. Gut Microbes 3 (2012), 366–373.
22. McVey Neufeld, K.A., Luczynski, P., Seira Oriach, C., et al. What's bugging your teen?-The microbiota and adolescent mental health. Neurosci Biobehav Rev 70 (2016), 300–312.
23. Goyal, M.S., Venkatesh, S., Milbrandt, J., et al. Feeding the brain and nurturing the mind: linking nutrition and the gut microbiota to brain development. Proc Natl Acad Sci U S A 112 (2015), 14105–14112.
24. Montiel-Castro, A.J., Gonzalez-Cervantes, R.M., Bravo-Ruiseco, G., et al. The microbiota-gut-brain axis: neurobehavioral correlates, health and sociality. Front Integr Neurosci, 7, 2013, 70.
25. Gershon, M.D., 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 20 (2013), 14–21.
26. Gross, E.R., Gershon, M.D., Margolis, K.G., et al. Neuronal serotonin regulates growth of the intestinal mucosa in mice. Gastroenterology 143 (2012), 408–417.e2.
27. Li, Z., Chalazonitis, A., Huang, Y.Y., et al. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons. J Neurosci 31 (2011), 8998–9009.
28. Margolis, K.G., Li, Z., Stevanovic, K., et al. Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function. J Clin Invest 126 (2016), 2221–2235.
29. Margolis, K.G., Stevanovic, K., Li, Z., et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut 63 (2014), 928–937.
30. Jenkins, T.A., Nguyen, J.C., Polglaze, K.E., et al. Influence of tryptophan and serotonin on mood and cognition with a possible role of the gut-brain axis. Nutrients, 8(1), 2016 [pii:E56].
31. Kennedy, P.J., Cryan, J.F., Dinan, T.G., et al. Kynurenine pathway metabolism and the microbiota-gut-brain axis. Neuropharmacology 112:Pt B (2017), 399–412.
32. Mittal, R., Debs, L.H., Patel, A.P., et al. Neurotransmitters: the critical modulators regulating gut-brain axis. J Cell Physiol 232:9 (2017), 2359–2372.
33. Morris, G., Berk, M., Carvalho, A., et al. The role of the microbial metabolites including tryptophan catabolites and short chain fatty acids in the pathophysiology of immune-inflammatory and neuroimmune disease. Mol Neurobiol 54:6 (2017), 4432–4451.
34. O'Mahony, S.M., Clarke, G., Borre, Y.E., et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 277 (2015), 32–48.
35. Moloney, R.D., Johnson, A.C., O'Mahony, S.M., et al. Stress and the microbiota-gut-brain axis in visceral pain: relevance to irritable bowel syndrome. CNS Neurosci Ther 22 (2016), 102–117.
36. Hyams, J.S., Di Lorenzo, C., Saps, M., et al. Functional disorders: children and adolescents. Gastroenterology 150 (2016), 1456–1468.
37. Van Oudenhove, L., Levy, R.L., Crowell, M.D., et al. Biopsychosocial aspects of functional gastrointestinal disorders: how central and environmental processes contribute to the development and expression of functional gastrointestinal disorders. Gastroenterology 150 (2016), 1355–1367.
38. Fond, G., Loundou, A., Hamdani, N., et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 264 (2014), 651–660.
39. Lackner, J.M., Brasel, A.M., Quigley, B.M., et al. The ties that bind: perceived social support, stress, and IBS in severely affected patients. Neurogastroenterol Motil 22 (2010), 893–900.
40. Mayer, E.A., Tillisch, K., The brain-gut axis in abdominal pain syndromes. Annu Rev Med 62 (2011), 381–396.
41. Halland, M., Almazar, A., Lee, R., et al. A case-control study of childhood trauma in the development of irritable bowel syndrome. Neurogastroenterol Motil 26 (2014), 990–998.
42. Park, S.H., Videlock, E.J., Shih, W., et al. Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity. Neurogastroenterol Motil 28 (2016), 1252–1260.
43. Gupta, A., Mayer, E.A., Acosta, J.R., et al. Early adverse life events are associated with altered brain network architecture in a sex- dependent manner. Neurobiol Stress 7 (2017), 16–26.
44. Sykes, M.A., Blanchard, E.B., Lackner, J., et al. Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J Behav Med 26 (2003), 361–372.
45. Rosen, J.M., Adams, P.N., Saps, M., Umbilical hernia repair increases the rate of functional gastrointestinal disorders in children. J Pediatr 163 (2013), 1065–1068.
46. Wilder-Smith, C.H., Schindler, D., Lovblad, K., et al. Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls. Gut 53 (2004), 1595–1601.
47. Tillisch, K., Mayer, E.A., Labus, J.S., Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 140 (2011), 91–100.
48. Phillips, M.L., Gregory, L.J., Cullen, S., et al. The effect of negative emotional context on neural and behavioural responses to oesophageal stimulation. Brain 126 (2003), 669–684.
49. Ringel, Y., Drossman, D.A., Leserman, J.L., et al. Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology 134 (2008), 396–404.
50. Mayer, E.A., Bradesi, S., Chang, L., et al. Functional GI disorders: from animal models to drug development. Gut 57 (2008), 384–404.
51. Iovino, P., Tremolaterra, F., Boccia, G., et al. Irritable bowel syndrome in childhood: visceral hypersensitivity and psychosocial aspects. Neurogastroenterol Motil, 21, 2009, 940-e74.
52. Di Lorenzo, C., Youssef, N.N., Sigurdsson, L., et al. Visceral hyperalgesia in children with functional abdominal pain. J Pediatr 139 (2001), 838–843.
53. Van Ginkel, R., Voskuijl, W.P., Benninga, M.A., et al. Alterations in rectal sensitivity and motility in childhood irritable bowel syndrome. Gastroenterology 120 (2001), 31–38.
54. Huang, J.S., Terrones, L., Simmons, A.N., et al. Pilot study of functional magnetic resonance imaging responses to somatic pain stimuli in youth with functional and inflammatory gastrointestinal disease. J Pediatr Gastroenterol Nutr 63 (2016), 500–507.
55. Gershon, M.D., Tack, J., The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132 (2007), 397–414.
56. Mawe, G.M., Hoffman, J.M., Serotonin signalling in the gut–functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 10 (2013), 473–486.
57. Faure, C., Patey, N., Gauthier, C., et al. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology 139 (2010), 249–258.
58. Gershon, M.D., Review article: serotonin receptors and transporters – roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 20:Suppl 7 (2004), 3–14.
59. Jadallah, K.A., Kullab, S.M., Sanders, D.S., Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol 20 (2014), 8898–8909.
60. Samuels, B.A., Mendez-David, I., Faye, C., et al. Serotonin 1A and serotonin 4 receptors: essential mediators of the neurogenic and behavioral actions of antidepressants. Neuroscientist 22 (2016), 26–45.
61. Ford, A.C., Moayyedi, P., Lacy, B.E., et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 109:Suppl 1 (2014), S2–S26 [quiz: S27].
62. Chang, L., Chey, W.D., Harris, L., et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 101 (2006), 1069–1079.
63. Tong, K., Nicandro, J.P., Shringarpure, R., et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Ther Adv Gastroenterol 6 (2013), 344–357.
64. Bahar, R.J., Collins, B.S., Steinmetz, B., et al. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr 152 (2008), 685–689.
65. Saps, M., Youssef, N., Miranda, A., et al. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 137 (2009), 1261–1269.
66. Tack, J., Broekaert, D., Fischler, B., et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 55 (2006), 1095–1103.
67. Vahedi, H., Merat, S., Rashidioon, A., et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 22 (2005), 381–385.
68. Roohafza, H., Pourmoghaddas, Z., Saneian, H., et al. Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Neurogastroenterol Motil 26 (2014), 1642–1650.
69. Rhee, S.H., Pothoulakis, C., Mayer, E.A., Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 6 (2009), 306–314.
70. Moayyedi, P., Ford, A.C., Talley, N.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59 (2010), 325–332.
71. Pirbaglou, M., Katz, J., de Souza, R.J., et al. Probiotic supplementation can positively affect anxiety and depressive symptoms: a systematic review of randomized controlled trials. Nutr Res 36 (2016), 889–898.
72. Pinto-Sanchez, M.I., Hall, G.B., Ghajar, K., et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology 153 (2017), 448–459.e8.
73. O'Mahony, L., McCarthy, J., Kelly, P., et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128 (2005), 541–551.
74. Whorwell, P.J., Altringer, L., Morel, J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101 (2006), 1581–1590.
75. Gawronska, A., Dziechciarz, P., Horvath, A., et al. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 25 (2007), 177–184.
76. Francavilla, R., Miniello, V., Magista, A.M., et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 126 (2010), e1445–e1452.
77. Horvath, A., Dziechciarz, P., Szajewska, H., Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 33 (2011), 1302–1310.
78. Giannetti, E., Maglione, M., Alessandrella, A., et al. A mixture of 3 Bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome: a multicenter, randomized, double-blind, placebo-controlled, crossover trial. J Clin Gastroenterol 51 (2017), e5–e10.
79. Guglielmetti, S., Mora, D., Gschwender, M., et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life–a double-blind, placebo-controlled study. Aliment Pharmacol Ther 33 (2011), 1123–1132.
80. Yoon, J.S., Sohn, W., Lee, O.Y., et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol 29 (2014), 52–59.
81. Guandalini, S., Magazzu, G., Chiaro, A., et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 51 (2010), 24–30.
82. Staudacher, H.M., Whelan, K., The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut 66 (2017), 1517–1527.
83. Halmos, E.P., Power, V.A., Shepherd, S.J., et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146 (2014), 67–75.e5.
84. Chumpitazi, B.P., Cope, J.L., Hollister, E.B., et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 42 (2015), 418–427.
85. Eswaran, S., Chey, W.D., Jackson, K., et al. A diet low in fermentable Oligo-, Di-, and Monosaccharides and Polyols improves quality of life and reduces activity impairment in patients with irritable bowel syndrome and diarrhea. Clin Gastroenterol Hepatol 15 (2017), 1890–1899.e3.
86. Ford, A.C., Quigley, E.M., Lacy, B.E., et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 109 (2014), 1350–1365 [quiz: 1366].
87. Rutten, J.M., Vlieger, A.M., Frankenhuis, C., et al. Gut-directed hypnotherapy in children with irritable bowel syndrome or functional abdominal pain (syndrome): a randomized controlled trial on self exercises at home using CD versus individual therapy by qualified therapists. BMC Pediatr, 14, 2014, 140.
88. Lackner, J.M., Lou Coad, M., Mertz, H.R., et al. Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety. Behav Res Ther 44 (2006), 621–638.
89. Frangos, E., Ellrich, J., Komisaruk, B.R., Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. Brain Stimul 8 (2015), 624–636.
90. Kovacic, K., Hainsworth, K., Sood, M., et al. Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial. Lancet Gastroenterol Hepatol 2 (2017), 727–737.
91. Camilleri, M., Di Lorenzo, C., Brain-gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr 54 (2012), 446–453.
92. Kaptchuk, T.J., Friedlander, E., Kelley, J.M., et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One, 5, 2010, e15591.
93. Benedetti, F., Pollo, A., Lopiano, L., et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 23 (2003), 4315–4323.
94. Finniss, D.G., Benedetti, F., Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain 114 (2005), 3–6.
95. Bradesi, S., Tillisch, K., Mayer, E., Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs 11 (2006), 293–313.
96. Mayer, E.A., Tillisch, K., Bradesi, S., Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 24 (2006), 919–933.
97. Martinez, V., Tache, Y., CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 12 (2006), 4071–4088.
98. Sweetser, S., Camilleri, M., Linker Nord, S.J., et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?. Am J Physiol Gastrointest Liver Physiol 296 (2009), G1299–G1306.